Aims/hypothesis miR-153 is an intronic miRNA embedded in the genes that encode IA-2 (also known as PTPRN) and IA-2β (also known as PTPRN2). Islet antigen (IA)-2 and IA-2β are major autoantigens in type 1 diabetes and are important transmembrane proteins in dense core and synaptic vesicles. miR-153 and its host genes are co-regulated in pancreas and brain. The present experiments were initiated to decipher the regulatory network between miR-153 and its host gene Ia-2β (also known as Ptprn2). Methods Insulin secretion was determined by ELISA. Identification of miRNA targets was assessed using luciferase assays and by quantitative real-time PCR and western blots in vitro and in vivo. Target protector was also employed to evaluate miRNA target function. Results Functional studies revealed that miR-153 mimic suppresses both glucose-and potassium-induced insulin secretion (GSIS and PSIS, respectively), whereas miR-153 inhibitor enhances both GSIS and PSIS. A similar effect on dopamine secretion also was observed. Using miRNA target prediction software, we found that miR-153 is predicted to target the 3′UTR region of the calcium channel gene, Cacna1c. Further studies confirmed that Cacna1c mRNA and protein are downregulated by miR-153 mimics and upregulated by miR-153 inhibitors in insulin-secreting freshly isolated mouse islets, in the insulin-secreting mouse cell line MIN6 and in the dopamine-secreting cell line PC12. Conclusions/interpretation miR-153 is a negative regulator of both insulin and dopamine secretion through its effect on Cacna1c expression, which suggests that IA-2β and miR-153 have opposite functional effects on the secretory pathway.
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Introduction
Islet antigen (IA)-2 and IA-2β are major autoantigens in type 1 diabetes [1] . Previous studies have shown that they are integral transmembrane proteins of dense core vesicles (DCVs) and/or synaptic vesicles [2, 3] . IA-2 and IA-2β are widely expressed in neuroendocrine cells throughout the body (e.g. pancreatic islets, brain, adrenals and gastrointestinal cells) [2] [3] [4] [5] . They are members of the transmembrane protein tyrosine phosphatase (PTP) family and are enzymatically inactive with standard PTP substrates owing to two critical amino acid substitutions in the PTP domain. However, recent studies suggest that IA-2β may have low phosphatidylinositol phosphatase activity [6] . IA-2 and IA-2β have been found to play important roles in the secretion of hormones and neurotransmitters such as insulin, luteinising hormone (LH) and follicular stimulating hormone (FSH), noradrenaline (norepinephrine, NE), dopamine, serotonin and renin, and reduction of these hormones results in glucose intolerance, female infertility, behavioural changes and loss of circadian rhythm [3, [7] [8] [9] [10] [11] [12] [13] [14] .
Recently, we showed that the microRNA, miR-153, is embedded in intron 19 of both IA-2 (also known as PTPRN and ICA512) and IA-2β (also known as PTPRN2) in humans and encodes two identical mature sequences (miR-153-1 and miR-153-2) [15] . In contrast, in the mouse and rat, miR-153 is found in the Ia-2β gene (also known as Ptprn2 and phogrin). The miR-153 precursor gives rise to two miRNA sequences, miR-153-3p and miR-153-5p, of which only miR-153-3p is identical to the human miR-153-2 and is highly conserved, evolutionarily, across different species [15] .
It is estimated that ∼37% of mammalian miRNAs are located within introns of protein coding genes [16] , and coregulation of these intragenic miRNAs and their host genes is a common biological phenomenon [15, 17] . Moreover, intronic miRNAs and their host genes, often tend to work in parallel, forming regulatory relationships between host genes and intronic miRNAs [18] . Based on the function of its host gene, Ia-2β, miR-153 is potentially linked to the secretion of hormones and neurotransmitters. Moreover, in a recent study we showed that in Ia-2β knockout mice, miR-153 is at least partly co-regulated with its host gene, Ia-2β [15] . However, the exact relationship between IA-2β, miR-153, and its target genes remains unclear. The present study was initiated to assess the functional effect of miR-153 on hormone and neurotransmitter secretion and to further our understanding of the relationship between the host gene Ia-2β, its intronic miR-153 and the gene targets of miR-153.
Methods
Mice Targeted disruption of the individual Ia-2 and Ia-2β genes (Ia-2 KO and Ia-2β KO) and generation of
−/− double knockout (DKO) mice have been described previously [7, 15] . Animals used in this study were from C57/BL6 background and produced in our institute animal core facility (National Institute of Dental and Craniofacial Research [NIDCR] , Bethesda, MD, USA). Lights were on from 06:00 to 18:00 and food and water were available ad libitum. All tissue samples harvested for this study were from age and sex-matched mice that were randomly selected from their home cage. Animal studies were conducted under protocols approved by the Institutional Animal Care and Use Committees of the National Institutes of Health (NIH), USA. Generation of Cacna1c 3′UTR reporter construct The method for constructing the wild-type (WT) and mutant luciferase reporter plasmids for miRNA target validation was adapted from a previous report [19] . After sequencing validation, plasmid DNA was prepared using a Plasmid Miniprep kit (Qiagen). For further details, see ESM Methods.
Cell lines
Transfection and luciferase reporter assays 293T cells were co-transfected with luciferase reporter plasmids (either a WT or mutant plasmid) and miR-153 mimic (Qiagen) or the scramble control (Qiagen), and the Renilla luciferase control vector (Promega, Madison, WI, USA), using Lipofecatamine 2000 (Life Technologies) according to the manufacturer's instructions. The luciferase activity assay was performed 24 h after transfection, using the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalised to Renilla luciferase activity.
Target protector functional analysis miR-153 miScript target protector (miR-153-Cacna1c) was designed to be complementary to the predicted miR-153 binding site in the Cacna1c 3′UTR (Qiagen). Transfection was performed according to the manufacturer's protocol. GSIS was performed 72 h later, together with quantitative real-time PCR for Cacna1c mRNA to assess the protective effect of the target protector. For further details, see ESM Methods.
Calcium microfluorimetry [Ca

2+
] i was measured using the ratiometric dye fura-2/AM (a high affinity, intracellular calcium indicator), with procedures modified from a previous report [20] . For further details, see ESM Methods.
Protein extraction and western blot analysis Proteins from cells or mouse tissues were isolated and then analysed by western blotting according to standard procedures. See ESM Methods for further details. Rabbit-anti-calcium channel, voltage-dependent, L type, α1C subunit (CACNA1C) antibody (1:500 dilution, Santa Cruz Biotech, Dallas, TX, USA) and mouse-anti-α-tubulin antibody (1:5,000 dilution, Abcam, Cambridge, MA, USA) were employed as primary antibodies. Blots were quantified using NIH Image J Software.
Statistical analysis Unless stated otherwise, each experiment was performed three times (n=3) and assayed in triplicate. Data are expressed as the mean ± SEM of the three experiments. The Student's t test for two groups or ANOVA for multiple groups were used to determine statistical significance. In all cases, p<0.05 was considered significant.
Results
The effect of miR-153 on insulin and dopamine secretion To evaluate the effect of miR-153 on insulin secretion, we used the mouse insulin-secreting cell line MIN6 and freshly isolated pancreatic islets from mice. Cells were transfected with a miR-153 mimic or inhibitor (ESM Fig. 1a , b) and analysed for GSIS and PSIS. Transfection of MIN6 cells with a miR-153 mimic, followed by glucose stimulation, led to a 25% reduction in insulin secretion. In contrast, miR-153 inhibitor led to a 30% increase in insulin secretion following glucose stimulation (Fig. 1a) . Similar results were obtained using freshly isolated mouse islets (Fig. 1b) . Stimulation with high potassium led to a 40-50% reduction in insulin secretion in the miR-153 mimic group and a 20-30% increase in insulin secretion in the miR-153 inhibitor group (Fig. 1c, d , respectively). These results clearly show that overexpression of miR-153 suppressed both GSIS and PSIS, whereas inhibition of endogenous miR-153 function enhanced insulin secretion.
Based on the high endogenous expression of miR-153 in brain and the role of its host genes in neurotransmitter secretion, we hypothesised that miR-153 would also play a role in the secretion of neurotransmitters. To test this hypothesis, we overexpressed or inhibited miR-153 in PC12 cells (ESM Fig. 1c) , a dopamine-secreting cell line, and measured dopamine secretion. PC12 cells transfected with miR-153 mimic, followed by potassium stimulation, led to a 15% reduction in dopamine secretion, whereas PC12 cells transfected with miR-153 inhibitor, followed by potassium stimulation, led to a 20% increase in dopamine secretion (Fig. 1e) . Stimulation of PC12 cells with both potassium and the protein kinase C (PKC) stimulator PMA [21] , led to a 20% decrease in dopamine secretion in the miR-153 mimic group and ∼25% increase in the miR-153 inhibitor group (Fig. 1f) . Taken together, these studies show that miR-153 is a negative regulator of both insulin and dopamine secretion.
GSIS occurs through the closure of ATP-sensitive K channels in the beta cell plasma membrane, resulting in cell depolarisation, activation of voltage-dependent calcium channels (VDCC) and a rise in islet [Ca 2+ ] i . In order to ascertain whether miR-153 regulates the activity of VDCCs, we used FURA2/AM to measure KCl-induced changes in [Ca 2+ ] i in control islets, or islets treated with either the miR-153 mimic or inhibitor. In the current study, we observed that 30 mmol/l KCl elicited a robust increase in [Ca 2+ ] i in control islets, and to a larger extent in islets treated with the miR-153 inhibitor (Fig. 1g) . Interestingly, the [Ca 2+ ] i response of islets treated with the miR-153 mimic were reduced compared with control islets or to the inhibitor group (Fig. 1g) , indicating that miR-153 acts on secretion at least in part by modulating VDCC activity.
Effect of miR-153 on calcium related target genes In order to identify potential targets of miR-153 that could affect insulin and dopamine secretion, the bioinformatics software Targetscan 6.2 and Pictar were employed. Within the list of miR-153 predicted targets, we found 11 calcium related targets. Five targets were identified by both software programs: Cacna1c, Cacnb4, Camk2g, Cask and Cib2. To experimentally validate the prediction, MIN6 cells were transfected with a miR-153 mimic or inhibitor. As seen in Fig. 2a , of the five targets identified, only Cacna1c and Cask had expression levels that were significantly reduced or increased after transfection with miR-153 mimic or miR-153 inhibitor. Given that the Cacna1c gene has been implicated in altering insulin secretion as well as neurotransmitters in vitro and in vivo [22] [23] [24] [25] , we chose to focus on the Cacna1c gene for further investigation.
Validation of an miR-153 target site in the Cacna1c 3′UTR To confirm that Cacna1c can be directly regulated by miR-153, a portion of the mouse Cacna1c gene 3′-UTR was cloned into a luciferase reporter vector. A mutated construct was also generated, in which the putative miR-153 binding site UAUGCAA was mutated into UAgagtA and then cloned into a luciferase reporter vector (Fig. 2b) . When compared with the reporter vector alone, luciferase activity was significantly reduced following transient co-transfection of miR-153 mimic with luciferase expression plasmid in 293T cells (Fig. 2c) . In contrast, transfection of 293T cells with scrambled control did not have any effect on the luciferase activity. However, mutations within the seed sequence binding site of Cacna1c abrogated the effect of miR-153 mimic (Fig. 2c) , thereby confirming that Cacna1c is a direct target of miR-153.
Regulation of endogenous Cacna1c expression by miR-153 in different cell lines Transfection of cell lines with a miR-153 mimic significantly reduced Cacna1c mRNA expression by nearly 50% as compared with the control in MIN6 cells, normal mouse islets and PC12 cells. In contrast, a significant increase in Cacna1c mRNA expression was observed in all three of these cells following transfection with the miR-153 inhibitor (Fig. 3a-c) . Western blot analysis confirmed the effects of miR-153 on the CACNA1C protein level in MIN6 cells and PC12 cells (Fig. 3d,e) . To rule out the possibility that miR-153 was exerting its effect through changes in the expression of its host gene, Ia-2β, we determined Ia-2β mRNA levels following transfection of the different cell lines with either miR-153 mimic or miR-153 inhibitor (Fig. 3f, g ). Our results showed that miR-153 has no effect on Ia-2β mRNA levels.
Effect of miR-153-Cacna1c target protector To confirm that the reduction of GSIS was due to miR-153 acting through its effect on the Cacna1c gene, a miR-153-Cacna1c target protector was employed. The target protector is a single-stranded modified RNA that is complementary to the miR-153 binding ] i responses after islet transfection with scrambled controls, miR-153 mimic or miR-153 inhibitor for 72 h, followed by stimulation with 30 mmol/l KCl. *p<0.05 and **p<0.01 vs controls site on the Cacna1c 3′UTR and specifically disrupts the interaction between miR-153 and Cacna1c 3′UTR. As seen in MIN6 cells (Fig. 4a) and freshly isolated mouse islets (Fig. 4b) , transfection with the miR-153-Cacna1c target protector abrogated, at least in part, the suppressive effect of exogenous miR-153 mimic on GSIS. This provides further evidence that the effect of miR-153 mimic on insulin secretion is mediated, at least in part, through Cacna1c gene regulation.
To determine the effect of miR-153-Cacna1c target protector on Cacna1c mRNA expression, quantitative real-time PCR was employed. In MIN6 cells (Fig. 4c) and freshly isolated mouse islets (Fig. 4d) , co-transfection of cells with miR-153 mimic and miR-153-Cacna1c target protector also abrogated, at least in part, the suppressive effect of exogenous miR-153 mimic on Cacna1c mRNA levels. Although in freshly isolated mouse islets, co-transfection of miR-153 mimic with miR-153-Cacna1c target protector did not fully restore Cacna1c mRNA expression to normal levels, a positive trend was observed (Fig. 4d) . The most likely explanation for the failure of the protector to fully restore GSIS is that it is specific to Cacna1c and therefore could not protect the degradation of other potential miR-153 targets involved in secretion.
miR-153 and Cacna1c expression in Ia-2β KO mice To determine whether the expression of Cacna1c is controlled by miR-153 in vivo, Ia-2β KO and DKO mice, in which miR-153 levels are dramatically reduced [15] , were used for expression correlation analysis. Our results showed that miR-153 levels are dramatically reduced in pancreatic islets from Ia-2β KO and DKO mice (Fig. 5a ) and also-although to a lesser extent-in the brain from these mice (Fig. 5b) . These observations are consistent with previous studies [15] . In contrast, miR-153 levels remain unchanged in pancreatic islets and brain from Ia-2 KO mice, thus supporting the idea that in mice miR-153 is only expressed from Ia-2β. Based on this information, we speculated that Cacna1c mRNA would be elevated in islets and brains from Ia-2β KO and DKO mice due to low expression of miR-153, but would not be elevated in Ia-2 KO mice. As anticipated, we found a significant increase in Cacna1c mRNA (Fig. 5c, d ) and protein (Fig. 5e, f) in both the islets and brain of Ia-2β KO and DKO mice, whereas no obvious change was observed in Ia-2 KO mice ( Fig. 5c-f ). These findings support the contention that the expression of Cacna1c in vivo is regulated, at least in part, by miR-153.
Discussion
Previously we showed that the knockout of the DCV transmembrane genes, Ia-2 and Ia-2β in mice, led to a decrease in the number of DCVs and resulted in a decrease in the secretion of hormones and neurotransmitters [3, 7, [10] [11] [12] . This in turn results in a variety of pathophysiological changes including glucose intolerance, female infertility, learning and behavioural disorders and dysregulation of circadian rhythm [3, 7, [9] [10] [11] 14] . The present experiments add support to previous studies that showed that the knockout of Ia-2β, but not Ia-2, results in a decrease in miR-153, which is embedded in intron 19 of the Ia-2β gene [15] . The current experiments also show that miR-153 mimics suppress hormone and neurotransmitter (e.g. insulin and dopamine) secretion, whereas miR-153 inhibitors enhance hormone and neuroendocrine secretion. Since miRNA function is mediated through its effect on a specific set of target genes, we undertook a bioinformatics search to identify miR-153 predicted target genes that might play a role in secretion. Our search identified 11 calcium channel related genes. Five of these gene targets were common in the two different prediction software algorithms that we used. Validation experiments in MIN6 cells confirmed the effect of miR-153 on the endogenous levels of two of these target genes, Cacna1c and Cask.
We focused on Cacna1c because of its well-known involvement in secretion and found that miR-153 mimic downregulated the expression of Cacna1c mRNA and protein, whereas miR-153 inhibitor upregulated the expression of Cacna1c mRNA and protein in MIN6 cells, normal mouse islets and dopamine-secreting PC12 cells. Thus, there is a complex relationship between IA-2β and miR-153. Hormone exocytosis and neurotransmitter release are fundamental cell biology processes and their regulation is essential for maintaining normal islet and brain function. The release of insulin and dopamine is tightly regulated and dependent on calcium entering cells following cell membrane depolarisation, with subsequent activation of voltage-gated calcium channels [24] [25] [26] [27] [28] . Cacna1c is a well-studied gene. The global knockout of Cacna1c in mice results in death at birth [29] , whereas beta cellspecific Cacna1c knockout does not result in death, but does result in strong inhibition of GSIS [23] . Other studies have shown that CACNA1C is physically coupled to a number of vesicle-release machinery proteins including the Rab3-interacting molecules (RIMs), Snap-25 and Syntaxin-1 [30] . Interestingly, Snap25 and Syntaxin-1 also are predicted targets of miR-153 [15, 31] . To determine the in vivo importance of this microRNA on the secretion of insulin and dopamine, specific knockout or overexpression of miR-153 in mice is required. The development of these knockout and transgenic mice is underway in our laboratory, but the already existing Ia-2β knockout mice may provide some clues as to what to expect. The Ia-2β, but not the Ia-2, knockout mice, showed a significant decrease of miR-153 and a significant increase of both Cacna1c mRNA and protein in the islets and brain. Thus, it is not unreasonable to expect an increase of CACNA1C in vivo following the specific knockout of miR-153. However, this prediction must be viewed with caution since miR-153 targets a number of genes unrelated to calcium channel genes which could directly or indirectly affect secretion.
Although in the current study we focused on the role of miR-153 on insulin and dopamine secretion, miR-153 has been shown to both suppress and enhance tumour growth and play a role in cell proliferation, migration and invasion [32] [33] [34] [35] [36] [37] . In addition, miR-153 is dysregulated in some cases of Parkinson's disease and Alzheimer's disease where it affects the expression of several disease-related targets such as α-synuclein, amyloid precursor protein and amyloid precursor-like protein 2 [38] [39] [40] [41] .
In conclusion, stimulation of the Ia-2β gene increases both IA-2β protein and miR-153 expression (Fig. 6) . The increase in IA-2β protein increases the number of DCV and in turn neuroendocrine secretion [3, 7, 10, 42] . In contrast, the increase in miR-153, which is a negative regulator, decreases Cacna1c expression and in turn suppresses neuroendocrine secretion. Thus, IA-2β and miR-153 have opposite functional effects on the secretory pathway. 
